| Mat Lade Mora Tutta La La La La Matatani Mata
Total Page:16
File Type:pdf, Size:1020Kb
|MAT LADE MORA TUTTA USLA 20170239307A1 LA LA LA MATATANI MATA ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0239307 A1 Villegas Becerril (43 ) Pub . Date : Aug. 24 , 2017 ( 54 ) COMPOSITION OF DOXYCYCLINE IN (30 ) Foreign Application Priority Data LIPOSOMES FOR THE PREVENTION , IMPROVEMENT AND /OR TREATMENT OF Sep . 23 , 2014 (ES ) .. P201431379 OCULAR PATHOLOGIES Dec . 16 , 2014 ( ES ) .. .. .. .. .. .. P201431854 Publication Classification (71 ) Applicant: AGENCIA PÚBLICA (51 ) Int. CI. EMPRESARIAL SANITARIA A61K 36 / 53 (2006 .01 ) HOSPITAL ALTO A61K 36 / 28 ( 2006 . 01 ) GUADALQUIVIR , Jaén (ES ) A61K 36 / 886 ( 2006 . 01 ) A61K 9 /00 (2006 . 01) (72 ) Inventor : Enrique Villegas Becerril, Jaén ( ES ) (52 ) U . S . CI. CPC . .. A61K 36 /53 (2013 . 01 ) ; A61K 9 /0048 (21 ) Appl . No .: 15 /513 , 493 ( 2013. 01 ) ; A61K 36 /28 ( 2013 .01 ) ; A61K 36 / 886 ( 2013 .01 ) ( 22 ) PCT Filed : Sep . 23 , 2015 ( 57 ) ABSTRACT The invention relates to use of a composition comprising (86 ) PCT No. : PCT/ ES2015 /070695 doxycycline in the production of a topically administered $ 371 ( c ) ( 1 ), medicament for the prevention , improvement and / or treat ( 2 ) Date : Mar. 22 , 2017 ment of ocular disorders . Patent Application Publication Aug . 24 , 2017 Sheet 1 of 6 US 2017 / 0239307 A1 XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX ????????? ??????????????????? ?????????????????? ??????????????????? ??????????????????? ???????????????? Schirmer' s test before ? 3030 . .. treatment mi 5555555555555555555*. * * * Schirmer' s test ' after . treatment - - Linear ( Schirmer' s test before treatment) * Linear ( Schirmer' s Uppy test after 1 2 3 4 5 6 7 8 9 10 11 12 treatment) Fig . 1 Patent Application Publication Aug . 24 , 2017 Sheet 2 of 6 US 2017 / 0239307 A1 * * . 8 Dry eye questionnaire score *- before treatment -* -* -* 8 Dry eye - - -* questionnaire score - *-. after treatment .* .* *:1,117199101141* .* 1 2 3 4 5 6 7 8 9 10 11 12 .* Fig . 2 Patent Application Publication Aug . 24 , 2017 Sheet 3 of 6 US 2017 / 0239307 A1 WWW 1200 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * = = = = = = = = = = = = = = = = = = = = = = = = = = = = 2.4*- 1000 . .- . * : ** * * * * * ** * * * * * * * * * * * * Total dry eye Total dry eye -. { { { ???? , ?? questionnaire score before treatment after teatment Fig . 3 Patent Application Publication Aug . 24 , 2017 Sheet 4 of 6 US 2017 / 0239307 A1 WWWWWWWWWWWWWWWWWWWWWWWWWWWWW * istanawi Hyperemia before treatment & Hyperemia after rrrrrrr treatment * o 1 2 3 5 6 7 8 9 10 11 12 Fig . 4 Patent Application Publication Aug . 24 , 2017 Sheet 5 of 6 US 2017 / 0239307 A1 kimli ter teatrix 20URI BIM Eto 3014604 288 SX TWO RXKINO WWWERE : : ) 20 389 : Fig . 5 Patent Application Publication Aug . 24 , 2017 Sheet 6 of 6 US 2017 / 0239307 A1 . .* . * *. * * * . 38 - * * comviriririw . .* . * * . 100 . * 682728 694 . * . * . *. * . * . * . * . * . * * $ 6 .& 55. 6 * OSDI Score before * treatment * OSDI Score after treatment * 12 5 6 8 9 10 Fig . 6 US 2017 /0239307 A1 Aug . 24 , 2017 COMPOSITION OF DOXYCYCLINE IN have already used topical doxycycline for the treatment of LIPOSOMES FOR THE PREVENTION , dry eye , although it has never been used for blepharitis IMPROVEMENT AND /OR TREATMENT OF treatment. OCULAR PATHOLOGIES 0007 ] Doxycycline has anti - infection effect and anti- in flammatory effect ( Wang et al ., 2008. Clin . Experiment. FIELD OF THE INVENTION Ophthalmol. 36 ( 1 ) , 8 - 12 ; Dursun et al. , 2008 . Am . J . Oph thalmol. 132 ( 1 ) , 8 - 13 ) . The amount of orally administered [ 0001 ] The present invention is comprised in the field of tetracycline may not reach sufficient concentration in the biology and medicine and relates to the use of doxycycline tear film where it exerts its function ( Smith et al . , 2008 . Br. for the prevention , improvement and / or treatment of ocular J. Ophthalmol. 92( 6 ), 856 - 859) . disorders . Preferably , the present invention relates to the [ 0008 ] Doxycycline has a protective effect on the walls of topical use of doxycycline in liposomes in the form of stable the microvasculature . In fact, it is used in the prevention of eye drops for the prevention , improvement and / or treatment aortic aneurysms through the inhibition of enzymes degrad of blepharitis , microthrombosis in the anterior pole and ing vessel walls . In certain groups of hemodialysis patients , chorioretinal vascular disorders . doxycycline proved to be effective in the prevention of thrombosis (Diskin et al ., 1998 . Nephron 78 , 365 - 368; Saran BACKGROUND OF THE INVENTION et al. , 2002 . Am . J . Kidney Dis . 40 , 1255 - 1263 ) . [0009 ] The protective effect of doxycycline on the vessel [0002 ] Blepharitis is one of the most common ophthalmo wall seems to be determined by metalloproteinase matrix logical diseases . It represents a wide range of acute and activity inhibition ( Sorsa et al. , 1994 . Ann . NY. Acad . Sci. chronic diseases characterized by inflammation of the free 732 , 375 -378 ) . margin of the eyelid . For both patients and ophthalmolo [0010 ] In a study conducted on rats , doxycycline was gists , this disease is very hard to understand , frustrating due capable of preventing aneurysmal dilatation without subse to its chronic nature and extremely tedious as a result of the quent signs of inflammation (Kaito et al. , 2003 . Surg. Today prolonged treatment it requires . 33, 426 -433 ) . In other work , patients taking doxycycline 10003 ] The free margin of the eyelid is the source of were found to have less vascular intimal layer proliferation inflammation which spreads to the cornea and bulbar con as well as less muscle cell migration ( Islam et al ., 2003 . Am . junctiva . This means that different types of patients are J. Pathol. 163 , 1557 -1566 ) . observed : patients with bulbar conjunctival vessel conges [0011 ] The physiopathology of diabetic retinopathy ( DR ) tion , with infiltration of the cornea and conjunctiva adnexa has yet to be fully clarified , but most authors attribute it to and pannus (vessel invasion into the peripheral cornea ) , vascular changes . In contrast , it has been recently discovered particularly in the inferior cornea . that there are changes in the glia and on a neuronal level that [ 0004 ] It is important to know the different manifestations may explain part of this physiopathology . ( Antonetti et al . , of blepharitis in order to apply suitable treatment (Raskin et 2012. N . Engl. J. Med . 366 ( 13 ) , 1227 - 1239 ) . Chronic al. , 1992 . Infect . Dis . Clin . North Am . 6 ( 4 ) , 777 -787 ) . More inflammatory changes occurring in DR in experimental than 80 agents responsible for blepharitis have been identi models include increased local nitric oxide production , fied ( Ostler, 1993 . Diseases of the external eye and adnexa , increased intracellular molecular adhesion , leukostasis and Baltimore , Williiams and Wilkins) , the most common ones increased cell expression by means of cytokines which are are Streptococus, Staphilococus, Pseudomonas, Moraxella in turn associated with tissue damage and neuronal damage and Actinomices , in addition to other not so common ones and loss ( Adamis et al. , 2008 . Semin . Immunopathol. 30 ( 2 ) , such as Anthrax , Pasteurella , Clostridium and Micobaste 65 -84 ; Tang et al ., 2011. Prog . Retin . Eye Res. 30 ( 5 ) , rium tuberculosis (Groden et al. , 1991. Cornea 10 ( 1 ) , 343 -358 ) . 50 - 53 ) . There are also other agents of viral origin (Mollus [0012 ] The microglia represents the first line of the cum contagiosum , Herpes simplex and Herpes zoster ) and immune system against attacks and usually remains inactive , fungi ( Coccidioides, Microsporum blastomices, Candida but in situations such as DR it is activated , inducing inflam and Aspergillus ) . Furthermore, there are also allergic disor matory changes (Rungger - Brändle et al. , 2000 . Invest . Oph ders ( atopy and contact dermatitis ) and other Steven - John thalmol. Vis Sci. 41 ( 7 ) , 1971 - 1980 ; Zeng et al. , 2000 . Vis son - type syndromes, ichthyosis or Lyell ’ s syndrome. Neurosci . 17 ( 3 ) , 463 -471 ; Zeng et al. , 2008 . Arch . Ophthal [ 0005 ] There are currently four blepharitis treatment alter mol. 126 ( 2 ) , 227 - 232 ; Barber et al ., 2005 . Invest Ophthalmol natives: eyelid hygiene , topical antibiotics, systemic antibi Vis Sci. 46 ( 6 ), 2210 - 2218 ; Gaucher et al . , 2007 . Vision Res . otics such as tetracyclines (Neiberg and Sowka , 2008 . 47 ( 5 ) , 612 -623 ; Ibrahim et al. , 2007. Diabetes 60 ( 4 ) , 1122 Optometry 79( 3 ) , 133 - 137) and corticosteroids. 1133; Krady et al. , 2005 . Diabetes 54 ( 5 ) , 1559 - 1565 ; Vin [0006 ] Keeping the free margin of the eyelid clean is cent et al. , 2007 . Diabetes 56 ( 1 ) :224 - 230 ) . fundamental for eliminating growing pathogens . Oral tetra [0013 ] Tetracycline and its derivatives have been proven cyclines are a fundamental complementary treatment to ease to have an anti - inflammatory effect and neuroprotective the symptoms of blepharitis (Dougherty et al. , 1991. Invest. effects , in addition to anti -bacterial effects , in cultures and in Ophthalmol . Vis . Sci. 132 ( 11 ) , 2970 - 2975 ) . Oral tetracy animal models. With respect to DR , some studies have clines are also used in certain apical corneal barrier disrup proven that doxycycline at low doses inhibits microglia tions (De Paiva et al. , 2006 . Invest. Ophthalmol. Vis . Sci . inflammatory changes , metalloproteinase activity and cell 47 ( 7 ) , 2847 - 56